An interventional study of AtriCure ISOLATOR Synergy Surgical Ablation System in Inappropriate Sinus Tachycardia, sponsored by AtriCure, Inc.. Active, not recruiting at 27 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by AtriCure, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Tachycardia with a site in United States — 4 open to participants now, 15 under way, none of them phase 3. Tachycardia · United States.
Among the 76 studies in Tachycardia with a site in United States, this one is the 18th largest by enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2022, is one of 31 with no phase, reaches primary completion later than 6 of the 14 other live ones, and was the 64th registered.
190 studies on the registry are indexed under Tachycardia; 24 are open to participants now.
Browse Tachycardia studies →4 of the 76 studies in Tachycardia with a site in United States are open now. Recruiting first, the newest first:
HeartBeam, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
Rush University Medical Center · Sites in United States
Ages 18+
University of Chicago · Sites in United States
Ages 18+
Medtronic · Sites in United States, Austria, Canada and 6 more countries
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Tachycardia studies recruiting now, 10 (56%) set no upper age limit and 3 (17%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 4 · Phase 4 9
First in 1996; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 81 across 118 interventional studies indexed under Tachycardia.
Median enrollment 57 across the 50 interventional studies, 232 across the 25 observational. Of the 56 that completed or were terminated, 25 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 76 have an industry lead sponsor. The 10 most frequent:
AtriCure, Inc. is the lead sponsor of 32 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
AtriCure, Inc. has 4 studies filed under Tachycardia — fewer than ten, so there is no comparison to draw.
5 of the studies in Tachycardia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00962728Alfredo GamboaBreathing Device in Postural Orthostatic Tachycardia Syndrome (POTS) | 2026-11 |
| NCT06138873Rush University Medical CenterAblation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy | 2026-11-23 |
| NCT01988883Vanderbilt University Medical CenterModafinil and Cognitive Function in POTS | 2026-12 |
| NCT02725060Vanderbilt University Medical CenterAutoimmune Basis for Postural Tachycardia Syndrome | 2027-02 |
| NCT05280093AtriCure, Inc.HEAL-IST IDE Trial | 2027-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 76 studies in Tachycardia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
Device: AtriCure ISOLATOR Synergy Surgical Ablation System
Hybrid sinus node sparing ablation procedure using the ISOLATOR Synergy Surgical Ablation System
Primary Effectiveness Endpoint
Freedom from IST at 12-months. Freedom from IST is defined as mean heart rate of ≤ 90bpm or at least a 15% reduction in mean heart rate as compared to baseline, in the absence of new or higher dosage of previously failed medications.
Time frame: 12-months Post Procedure
Primary Safety Endpoint
Incidence of device or procedure-related major adverse events (MAEs) for subjects undergoing the hybrid sinus node sparing ablation procedure from the index procedure through 30-days post procedure
Time frame: 30-days Post Procedure
6-Minute Walk Test
Change in 6-Minute Walk Test (6-MWT) from baseline compared to 6-, 12- and 24-months post-procedure
Time frame: 24-months Post Procedure
Borg dyspnea score
Change in Borg dyspnea severity of breathlessness and fatigue score from baseline compared to 6-, 12- and 24-months post-procedure. Borg dyspnea score will be assessed at each of the 6-MWT.
Time frame: 24-months Post Procedure
Self-Rating Anxiety Scale
Change from baseline in psychological evaluation compared to 6-, 12- and 24-months post-procedure utilizing the Self-Rating Anxiety Scale (SAS)
Time frame: 24-months Post Procedure
IST symptom reduction
IST symptom reduction at baseline to 6-, 12- and 24-months post-procedure
Time frame: 24-months Post Procedure
QoL - SF-12
Change in QoL based on a Short Form Survey (SF-12) domain and component scores at baseline compared to 6-, 12- and 24-months post-procedure
Time frame: 24-months Post Procedure
Mean heart rate
Change in mean heart rate at 6-, 12- and 24-months post-procedure compared to baseline, using 7-day continuous monitoring
Time frame: 24-months Post Procedure
Reduction in mean heart rate in the absence of rate control drugs
Freedom from IST or at least 15% reduction in mean heart rate at 12- and 24-months compared to baseline, in the absence of rate control drugs (beta-blockers/calcium channel blockers, ivabradine) and/or AADs
Time frame: 24-months Post Procedure
Reduction in mean heart rate regardless of rate control drugs
Freedom from IST or at least a 15% reduction in mean heart rate at 12- and 24-months compared to baseline, regardless of rate control drugs (beta-blockers/calcium channel blockers, ivabradine) and/or AADs
Time frame: 24-months Post Procedure
Device or procedure related Serious Adverse Events
Device or procedure related Serious Adverse Events (SAEs) through 12-months
Time frame: 12-months Post Procedure
Improved heart rate variability - 7-day monitor
Improved heart rate variability for subjects using 7-day continuous monitoring
Time frame: 12-months Post Procedure
Improved heart rate variability - Implantable loop recorder
Improved heart rate variability and activity levels for subjects with implantable loop recorders (ILRs)
Time frame: 12-months Post Procedure
Health Economics
Health Economics: ER visits and readmissions
Time frame: 24-months Post Procedure
Plan to share: No
Started May 2022 (actual). Primary completion is estimated for Feb 2027, 57 months after the start.
Of 38 interventional studies with no phase under Tachycardia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 36. This study's planned 57 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.